J. Ewing, Diffuse Endothelioma of Bone, Proceedings of the New York Pathological Society, vol.22, pp.95-103, 1921.

H. W. Hense, S. Ahrens, M. Paulussen, M. Lehnert, and H. Jürgens, Descriptive epidemiology of Ewing's tumor-analysis of German patients from (EI)CESS 1980-1997, Klinische Padiatrie, vol.211, pp.271-276, 1999.

C. A. Stiller, S. S. Bielack, G. Jundt, and E. Steliarova-foucher, Report from the Automated Childhood Cancer Information System project, European Journal of Cancer, vol.42, pp.2124-2159, 1978.

R. Jaffe, M. Santamaria, and E. J. Yunis, The neuroectodermal tumor of bone, American Journal of Surgical Pathology, vol.8, pp.885-98, 1984.

A. L. Folpe, E. M. Chand, J. R. Goldblum, and S. W. Weiss, Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics, American Journal of Surgical Pathology, vol.25, pp.1061-1067, 2001.

W. A. May, M. L. Gishizky, and S. L. Lessnick, Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation, Proceedings of the National Academy of Sciences USA, vol.90, pp.5752-5758, 1993.

F. Nakatani, K. Tanaka, and R. Sakimura, Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein, Journal of Biological Chemistry, vol.278, pp.15105-15120, 2003.

L. Dauphinot, D. Oliveira, C. Melot, and T. , Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression, Oncogene, vol.20, pp.3258-65, 2001.

N. J. Balamuth and R. B. Womer, Ewing's sarcoma, Lancet Oncology, vol.11, pp.184-92, 2010.

R. Taylor, H. J. Knowles, and N. A. Athanasou, Ewing sarcoma cells express RANKL and support osteoclastogenesis, Journal of Pathology, vol.225, pp.195-202, 2011.

J. M. Chirgwin and T. A. Guise, Molecular mechanisms of tumor-bone interactions in osteolytic metastases, Critical Reviews in Eukaryotic Gene Expression, vol.10, pp.159-78, 2000.

W. S. Simonet, D. L. Lacey, and C. R. Dunstan, Osteoprotegerin: a novel secreted protein involved in the regulation of bone density, Cell, vol.89, pp.309-328, 1997.

Y. Wittrant, S. Théoleyre, and C. Chipoy, RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis, Biochimica et Biophysica Acta, vol.1704, pp.49-57, 2004.
URL : https://hal.archives-ouvertes.fr/inserm-00669006

D. L. Lacey, E. Timms, and H. L. Tan, Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, vol.93, pp.165-76, 1998.

S. Theoleyre, Y. Wittrant, S. K. Tat, Y. Fortun, F. Rédini et al., The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling, Cytokine and Growth Factor Reviews, vol.15, pp.457-75, 2004.

A. Mizuno, N. Amizuka, and K. Irie, Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochemical and Biophysical, Research Communications, vol.247, pp.610-615, 1998.

N. Bucay, I. Sarosi, and C. R. Dunstan, Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification, Genes and Development, vol.12, pp.1260-1268, 1998.

L. C. Hofbauer, A. Neubauer, and A. E. Heufelder, Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases, Cancer, vol.92, pp.460-70, 2001.

E. Grimaud, L. Soubigou, and S. Couillaud, Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis, American Journal of Pathology, vol.163, pp.2021-2052, 2003.

P. I. Croucher, C. M. Shipman, and J. Lippitt, Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma, Blood, vol.98, pp.3534-3574, 2001.

S. Morony, C. Capparelli, I. Sarosi, D. L. Lacey, C. R. Dunstan et al., Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis, Cancer Research, vol.61, pp.4432-4438, 2001.

F. Lamoureux, P. Richard, and Y. Wittrant, Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption, Cancer Research, vol.67, pp.7308-7326, 2007.

J. Rousseau, V. Escriou, and P. Perrot, Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models, Cancer Gene Therapy, vol.17, pp.387-97, 2010.

J. G. Emery, P. Mcdonnell, and M. B. Burke, Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL, Journal of Biological Chemistry, vol.273, pp.14363-14370, 1998.

I. Holen, P. I. Croucher, F. C. Hamdy, and C. L. Eaton, Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells, Cancer Research, vol.62, pp.1619-1642, 2002.

C. M. Shipman and P. I. Croucher, Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells, Cancer Research, vol.63, pp.912-918, 2003.

B. Pitard, H. Pollard, and O. Agbulut, A nonionic amphiphile agent promotes gene delivery in vivo to skeletal and cardiac muscles, Human Gene Therapy, vol.13, pp.1767-75, 2002.

B. Pitard, M. Bello-roufai, and O. Lambert, Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer, Nucleic Acids Research, vol.32, p.159, 2004.

L. Desigaux, C. Gourden, and M. Bello-roufai, Nonionic amphiphilic block copolymers promote gene transfer to the lung, Human Gene Therapy, vol.16, pp.821-830, 2005.

P. Richard, F. Bossard, L. Desigaux, C. Lanctin, M. Bello-roufai et al., Amphiphilic block copolymers promote gene delivery in vivo to pathological skeletal muscles, Human Gene Therapy, vol.16, pp.1318-1342, 2005.

F. Lamoureux, G. Picarda, L. Garrigue-antar, M. Baud'huin, V. Trichet et al., Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma, Cancer Research, vol.69, pp.526-562, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01680055

M. J. Rogers, S. Gordon, H. L. Benford, F. P. Coxon, S. P. Luckman et al., Cellular and molecular mechanisms of action of bisphosphonates, Cancer, vol.88, pp.2961-78, 2000.

D. Heymann, B. Ory, F. Blanchard, M. F. Heymann, P. Coipeau et al., Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma, Bone, vol.37, pp.74-86, 2005.

G. A. Odri, S. Dumoucel, G. Picarda, S. Battaglia, F. Lamoureux et al., Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients, Cancer Research, vol.70, pp.7610-7619, 2010.

S. Battaglia, S. Dumoucel, J. Chesneau, M. F. Heymann, G. Picarda et al., Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient, Journal of Bone and Mineral Research, vol.26, pp.2439-51, 2011.

L. C. Hofbauer and A. E. Heufelder, Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology, Journal of Molecular Medicine, vol.79, pp.243-53, 2001.

R. J. Thomas, T. A. Guise, and J. J. Yin, Breast cancer cells interact with osteoblasts to support osteoclast formation, Endocrinology, vol.140, pp.4451-4459, 1999.

S. Kitazawa and R. Kitazawa, RANK ligand is a prerequisite for cancer-associated osteolytic lesions, Journal of Pathology, vol.198, pp.228-264, 2002.

Y. Wittrant, S. Theoleyre, and C. Chipoy, RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis, Biochimica et Biophysica Acta, vol.1704, pp.49-57, 2004.
URL : https://hal.archives-ouvertes.fr/inserm-00669006

D. H. Jones, T. Nakashima, and O. H. Sanchez, Regulation of cancer cell migration and bone metastasis by RANKL, Nature, vol.440, pp.692-698, 2006.

D. R. Clohisy, M. L. Ramnaraine, S. Scully, M. Qi, H. L. Van et al., Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice, Journal of Orthopaedic Research, vol.18, pp.967-76, 2000.

N. M. Luger, P. Honore, and M. A. Sabino, Osteoprotegerin diminishes advanced bone cancer pain, Cancer Research, vol.61, pp.4038-4085, 2001.

K. Vanderkerken, D. Leenheer, E. Shipman, and C. , Recombinant Osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma, Cancer Research, vol.63, pp.287-296, 2003.

H. Yonou, N. Kanomata, and M. Goya, Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice, Cancer Research, vol.63, pp.2096-102, 2003.

J. G. Emery, P. Mcdonnell, M. B. Burke, K. C. Deen, S. Lyn et al., Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL, Journal of Biological Chemistry, vol.273, pp.14363-14370, 1998.

F. Lamoureux, G. Moriceau, G. Picarda, J. Rousseau, V. Trichet et al., Regulation of osteoprotegerin pro-or anti-tumoral activity by bone tumor microenvironment, Biochimica et Biophysica Acta, vol.1805, pp.17-24, 2010.

P. J. Bekker, D. L. Holloway, A. S. Rasmussen, R. Murphy, S. W. Martin et al., A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women, Journal of Bone and Mineral Research, vol.19, pp.1059-66, 2004.

P. J. Kostenuik, H. Q. Nguyen, J. Mccabe, K. S. Warmington, and C. Kurahara, Sun Net al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL, Journal of Bone and Mineral Research, vol.24, pp.182-95, 2009.

E. Terpos, E. Efstathiou, D. Christoulas, M. Roussou, E. Katodritou et al., RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases, Expert Opinion on Biological Therapy, vol.9, pp.465-79, 2009.

Y. S. Lau, I. E. Adamopoulos, A. Sabokbar, H. Giele, C. L. Gibbons et al., Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma, British Journal of Cancer, vol.96, pp.1716-1738, 2007.